<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>A 6-year-old, male, neutered, English Mastiff dog was presented for a second opinion due to chronic pruritus. The patient had been on methylprednisolone and chlorphenamine for four years. The diagnostic investigations included: swabs for bacterial and mycology culture, hair plugs for dermatophyte culture, acetate tape strips and deep skin scrapes, skin biopsies for dermatohistopathology, biochemistry, haematology, endocrinology, serology for canine scabies using enzyme-linked immunosorbent assay (ELISA) testing and serology for allergen specific IgE antibodies. The history and the diagnostics confirmed the diagnosis of canine atopic dermatitis. This case report details the treatment with lokivetmab, which is a caninised monoclonal antibody drug. At periods of flare ups, additional treatments were prescribed, such as systemic glucocorticoids and oclacitinib in order to manage the clinical signs. The treatment showed good response to the overall treatment management during the three year period of this atopic patient.</p>
</abstract>

A 6-year-old, male, neutered, English Mastiff dog was presented for a second opinion due to chronic pruritus. The patient had been on methylprednisolone and chlorphenamine for four years. The diagnostic investigations included: swabs for bacterial and mycology culture, hair plugs for dermatophyte culture, acetate tape strips and deep skin scrapes, skin biopsies for dermatohistopathology, biochemistry, haematology, endocrinology, serology for canine scabies using enzyme-linked immunosorbent assay (ELISA) testing and serology for allergen specific IgE antibodies. The history and the diagnostics confirmed the diagnosis of canine atopic dermatitis. This case report details the treatment with lokivetmab, which is a caninised monoclonal antibody drug. At periods of flare ups, additional treatments were prescribed, such as systemic glucocorticoids and oclacitinib in order to manage the clinical signs. The treatment showed good response to the overall treatment management during the three year period of this atopic patient.

A 3-Year Case Report on an Atopic Patient with a Caninised Monoclonal Antibody Treatment

Folia Veterinaria

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

A 6-year-old, male, neutered, English Mastiff dog was presented for a second opinion due to chronic pruritus. The patient had been on methylprednisolone and...

A 3-Year Case Report on an Atopic Patient with a Caninised Monoclonal Antibody Treatment

Data publikacji: 31 mar 2022

Zakres stron: 42 - 48

Otrzymano: 07 sty 2022

Przyjęty: 18 lut 2022

DOI: https://doi.org/10.2478/fv-2022-0005

Słowa kluczowe
canine atopic dermatitis, CAD, caninised monoclonal antibody, lokivetmab, mAb

© 2022 P. Petrou, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

A 3-Year Case Report on an Atopic Patient with a Caninised Monoclonal Antibody Treatment

Data publikacji: 31 mar 2022

Zakres stron: 42 - 48

Otrzymano: 07 sty 2022

Przyjęty: 18 lut 2022

DOI: https://doi.org/10.2478/fv-2022-0005

Słowa kluczowecanine atopic dermatitis, CAD, caninised monoclonal antibody, lokivetmab, mAb

© 2022 P. Petrou, published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Słowa kluczowe
canine atopic dermatitis, CAD, caninised monoclonal antibody, lokivetmab, mAb